ArticleInternational journal of molecular sciences2025
Adjuvant Systemic Immunotherapies for Resected Stage III Melanoma: A Single-Centre Retrospective Clinical Practice Review.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma poses significant challenges due to its resistance to conventional therapies and increasing incidence rates. Stage III melanoma, characterised by regional lymph node involvement, has a high risk of recurrence despite surgical resection. Adjuvant immunotherapy, particularly using the PD-1 inhibitors pembrolizumab and nivolumab, has shown promising results in improving recurrence-free survival (RFS) and overall survival (OS) in Stage III melanoma patients. This retrospective analysis examined the effects of adjuvant pembrolizumab or nivolumab on patients with Stage III melanoma treated in a tertiary oncology centre. Of the 110 patients, 95 received pembrolizumab and 15 received nivolumab. The pembrolizumab completion rate was 62.1%, with 31.2% discontinuing due to disease progression or adverse effects. The nivolumab completion rate was lower at 40%, with 60% discontinuing due to toxicity or disease progression. Grade 3 or higher toxicities were observed in 17% of pembrolizumab and 53.3% of nivolumab patients. Disease progression occurred in 27.4% of pembrolizumab and 26.7% of nivolumab patients. Pembrolizumab showed a 12-month RFS of 78.9% and 24-month RFS of 77.6%, with an OS of 97.9% at 12 months. Nivolumab exhibited a 12-month RFS of 86.7% and 24-month RFS of 80%. RFS rates varied by disease stage and mutation status. Adjuvant pembrolizumab and nivolumab both demonstrate efficacy in improving RFS and OS in Stage III melanoma patients. Pembrolizumab has higher completion rates and fewer toxicities compared to nivolumab. Further studies are warranted to explore long-term outcomes and optimise treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.